MAR 28, 2017 4:58 PM PDT

Dormant HIV Can Run, But It Can't Hide

WRITTEN BY: Kara Marker

Two drugs have synergistic potential to control human immunodeficiency virus (HIV). Administered immediately following infection, these two anti-HIV antibodies empower the immune system to fight of HIV on its own and keep the infection at bay long-term.

Working in a monkey model of HIV, scientists discovered that a dual-antibody therapy can boost the immune system to control the infection and prevent the virus from returning. Credit: Rockefeller University

"This form of therapy can induce potent immunity to HIV, allowing the host to control the infection," said Michel Nussenzweig. "It works by taking advantage of the immune system's natural defenses, similar to what happens in some forms of cancer immunotherapy."

Nussenzweig and a team of researchers from Rockefeller University and the National Institutes of Health used macaque monkeys and a model of HIV infection called simian-human immunodeficiency virus (SHIV) to study the effects of the two experimental drugs.

SHIV is a recombinant virus developed specifically to be a research tool for studying HIV in a non-human primate setting. The virus includes characteristics of the HIV envelope that affect transmission and pathogenesis, and using SHIV in a study allows for the evaluation of the efficacy of anti-HIV microbicide formulations and vaccines.

The two drugs tested in the new study, 3BNC117 and 10-1074, are broadly neutralizing antibodies (bNAbs) that each bind to a different site on HIV.. As their name suggests, bNAbs are capable of neutralizing a variety of virus subtypes. 3BNC117 and 10-1074 were discovered in Nussenzweig’s laboratory during a study of rare individuals whose immune systems are able to fight HIV all on their own.

Over two weeks, 13 monkeys were given SHIV infections followed by three intravenous infusions of 3BNC117 and 10-1074. For about six months, the two drugs reduced viral levels to near or below the limit of detection. After the antibody levels gradually declined over time, SHIV levels returned in all but one monkey. However, several months later, six monkeys “spontaneously regained control of the virus.”

Like they did when the monkeys were initially inoculated with the two drugs, viral levels were reduced to undetectable levels and remained like that for several months. For four monkeys who did not spontaneously regain control over SHIV, they nonetheless appeared somewhat able to control the virus, showing low viral loads and healthy levels of key SHIV-fighting immune cells several years after infection.

Researchers from this study are ready to test the two drugs in human cases of HIV, and they expect similar results, because their research indicates humans and macaques contain similar immune cell profiles involved in the anti-HIV immune response. The present study was published in the journal Nature.

Sources: InTech, Acta Naturae, Rockefeller University

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 30, 2020
Immunology
Sunshine Could Lower Your Risk of Developing MS
JUL 30, 2020
Sunshine Could Lower Your Risk of Developing MS
In multiple sclerosis, or MS, the insulating sheaths around nerve cells in the brain and spinal cord called myelin becom ...
AUG 05, 2020
Coronavirus
Age-old Immune Components Affecting COVID-19 Severity
AUG 05, 2020
Age-old Immune Components Affecting COVID-19 Severity
One of the most unsettling aspects of the coronavirus pandemic is the wide range of severity those affected seem to expe ...
AUG 17, 2020
Immunology
Nervous Protein Neuromedin B May Prevent Immune Reactivity
AUG 17, 2020
Nervous Protein Neuromedin B May Prevent Immune Reactivity
A protein produced by the nervous system seems to play a role in regulating the immune system. For people with inflammat ...
SEP 13, 2020
Drug Discovery & Development
Scientists Find Way to Reduce Inflammation from Vaccines
SEP 13, 2020
Scientists Find Way to Reduce Inflammation from Vaccines
Researchers from the University of Chicago have found a new way to reduce vaccine-related inflammation from adjuvants, a ...
SEP 17, 2020
Immunology
COVID Vaccine Works in Macaques - What about in Humans?
SEP 17, 2020
COVID Vaccine Works in Macaques - What about in Humans?
Pharmaceutical giant Pfizer, in partnership with BioNTech has reported that one of its lead vaccine candidates has shown ...
NOV 16, 2020
Immunology
Measles Is Back and COVID Isn't Helping
NOV 16, 2020
Measles Is Back and COVID Isn't Helping
Measles is a highly contagious and airborne viral disease. There is no treatment besides supportive care once a person b ...
Loading Comments...